HRTX
Heron Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 3
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
Revenue Beats Expectation
RSI Overbought
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About HRTX
Heron Therapeutics, Inc.
A commercial-stage biotechnology company that develops therapeutics used in nausea and vomiting prevention, pain management, and to treat inflammation
100 Regency Forest Drive, Suite 300, Cary, North Carolina 27518
--
Heron Therapeutics, Inc. The company was founded in February 1983 in California as AMCO Polymerics Corporation (AMCO). AMCO changed its name to Advanced Polymer Systems in 1984 and was re-incorporated in Delaware in 1987. The company, which changed its name to AP Pharma in May 2001 to reflect its new pharmaceutical focus, is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve healthcare. The company's main focus is on its leading product candidate, APF 530, which was developed for the prevention of chemotherapy-induced nausea and vomiting (CINV). The company's core Biochronomer technology includes biocorrosive polymers designed to release drugs within a specified period of time, and its APF 530 and other product candidates are developed based on this technology. The company has completed more than 100 in vivo and in vitro studies, and the results show that the company's Biochronomer technology may be applicable to a variety of therapeutic areas, including prevention of nausea and vomiting, pain management, inflammation control and ophthalmic disease treatment. The company also completed comprehensive animal and human toxicology studies and concluded that its Biochronomer polymer is safe and well tolerated. In addition, the company's Biochronomer technology can be used to release drugs within days or months.
Earnings Call
Q2/2025
Estimate EPS-0.01
Actual EPS-0.02
Estimate Revenue38.08M
Actual Revenue37.20M
Contradictions in 2025 Q2 Earnings Call: Sales Force Restructuring and APONVIE Dynamics Unraveled
Aug 08,2025 03:50
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
HRTX has released its 2025 Q3 earnings. EPS was reported at -0.1, versus the expected -0.01, missing expectations. The chart below visualizes how HRTX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
HRTX has released its 2025 Q3 earnings report, with revenue of 38.21M, reflecting a YoY change of 16.47%, and net profit of -17.50M, showing a YoY change of -260.87%. The Sankey diagram below clearly presents HRTX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
